Corticosteroid myopathies …

Neuromuscular Disorders

Updated 02.19.2023
Released 04.28.1995
Expires For CME 02.19.2026

Corticosteroid myopathies

Authors: Aziz I Shaibani MD, Husam Al Sultani MD

See Contributor Disclosures

Editor: Aravindhan Veerapandiyan MD

Corticosteroid myopathies

In This Article

Quick Link

Introduction

Overview

Exposure to endogenous or exogenous corticosteroids may produce myopathy. A particularly interesting entity is severe myopathy occurring in critically ill patients exposed to high-dose corticosteroids and neuromuscular blocking agents. In this updated article, the authors will refer to the common problem of distinguishing steroid myopathy from an underlying inflammatory muscle disease. When glucocorticoids are tapered in this situation, the patient must be monitored for a flare of the underlying condition (in particular, rise of CK) and for signs of evolving adrenal insufficiency. Improved strength within 3 to 4 weeks after corticosteroid tapering is a good indicator that the weakness was indeed due to the drug and not to the underlying inflammatory muscle disease.

Key points

	• Patients treated with corticosteroids may develop myopathy months to years after initiation of therapy.
	• Stopping the corticosteroid, lowering the dose, and switching to a nonfluorinated preparation are the mainstays of management.
	• Critical illness myopathy is a severe, acute myopathy that may be triggered by high-dose corticosteroids and nondepolarizing neuromuscular blocking agents.
	• Early mobilization of patients seems to be very effective in the management of critical illness myopathy.

Historical note and terminology

The development of proximal muscle weakness and atrophy from excessive endogenous glucocorticoid production in patients with pituitary adenomas was first noted 75 years ago by Cushing (14). Subsequent studies confirmed that myopathy was a common complication of chronic exogenous corticosteroid administration. Dubois observed that profound weakness was the most serious adverse effect of triamcinolone, a new synthetic fluorinated corticosteroid (17).

High-dose corticosteroids may trigger critical illness myopathy, in particular, among patients with prolonged intensive care unit (ICU) stay, mechanical ventilation, or persistent systemic inflammation (35; 36). A severe, acute myopathy that prolongs ventilator dependence has been described in patients treated with high-dose corticosteroids, many of whom also received nondepolarizing neuromuscular blocking agents (25). The first patient reported with this acute form of steroid myopathy was a 24-year-old woman placed on large doses of intravenous hydrocortisone (up to 3 g a day) for status asthmaticus (40). After 8 days, her airway obstruction resolved, but she was unable to resist gravity in both proximal and distal muscles. She gradually improved and could walk unassisted after 3 weeks but continued to have distal leg weakness after 2 months. Since this initial description, many additional patients have been reported in the literature (25; 33; 34). However, most prospective studies could not identify corticosteroids as an independent risk factor for critical illness myopathy, as summarized in a Cochrane review (24). Similarly, ICU-acquired neuromyopathy was common (34%) among 128 survivors of persistent acute respiratory distress syndrome but was not significantly associated with methylprednisolone treatment (28). Differential diagnosis between critical illness myopathy and critical illness polyneuropathy is important, as prognosis is more favorable in critical illness myopathy (35; 36). Critical illness myopathy and critical illness polyneuropathy are discussed in detail in another MedLink summary.

Clinical manifestations

Presentation and course

Patients treated with corticosteroids may develop myopathy months to years after initiation of therapy. The myopathy produced by chronic steroid excess is characterized by various degrees of painless, proximal weakness with legs more involved than arms. The face, bulbar musculature, and sphincters are spared. Muscle wasting and myalgias may be prominent in the extremities. Reflexes are preserved. Other stigmata of corticosteroid toxicity, such as a Cushing appearance and fragile skin, invariably accompany the muscle weakness. Atrophy and weakness are accelerated in the setting of malnutrition, disuse, endocrinopathy, or debilitating illness.

Myopathy may be a complication of pituitary and adrenal adenomas, though modern reports of myopathy resulting from Cushing syndrome are rare (33). The myopathy in these patients resembles the clinical syndrome produced by exogenous steroids. The muscle weakness has been attributed to excess endogenous corticosteroid production, and the weakness usually reverses when glucocorticoid levels normalize. However, elevated levels of adrenocorticotropic hormone in Cushing disease may be the direct cause of myopathy (19; 29).

The acute form of steroid myopathy is difficult to define on clinical grounds. Reports have varied widely in regard to the steroid preparation and dosages used, underlying medical conditions, and concomitant therapy, especially neuromuscular blocking agents. Despite these limitations, a few clinical observations have emerged. Approximately two thirds of patients were placed on high-dose corticosteroids for management of status asthmaticus (25). Another 20% to 25% had recent traumatic injuries. About 90% of patients also received nondepolarizing neuromuscular blocking agents for 4 to 21 days, usually pancuronium or vecuronium. Nearly all had received sedatives. Other associated factors include acidosis, elevated serum magnesium levels, hepatic or renal dysfunction, and aminoglycoside administration (20). In some reported cases, patients have received only corticosteroids (39; 48).

Most patients who develop the myopathy have received a cumulative equivalent dose exceeding 1000 mg of methylprednisolone (34). This form of myopathy may develop in critically ill patients without exposure to corticosteroids or neuromuscular blocking agents (15). Diffuse weakness developed as early as 4 days to 7 days after initiation of corticosteroids (25; 05). Complete flaccid quadriplegia develops in some patients, especially those receiving more than 80 mg total of vecuronium (34). In a series, distal limb and facial weakness were present in most patients (34). Extraocular muscles were involved in 1 of 14 patients. Sun and colleagues describe a patient presenting with acute flaccid hemiplegia, subsequently progressing to triplegia (60). The occurrence of a second episode of acute quadriplegic myopathy during a subsequent intensive care unit admission has been described (32; 39).

Up to half of patients with adrenal insufficiency (Addison disease) report generalized weakness (29). Similar symptoms are experienced by patients being withdrawn from exogenous corticosteroids, particularly after high-dose, long-term administration. These patients also may experience arthralgias, weight loss, skin changes, and fever. Muscle enzymes in serum and EMG are normal. The muscle biopsy is also normal except for diminished glycogen. The mild weakness and fatigue of Addison disease are rapidly corrected by hormone replacement. Similarly, slowing the taper will improve symptoms of steroid withdrawal.

Concurrent electrolyte imbalances or other endocrine disturbances are typically present with objective myopathic findings in patients with Addison disease. Therefore, severe weakness in a patient with Addison disease should prompt further investigation.

Prognosis and complications

Hypotension, fasting hypoglycemia, and severe anorexia are frequent complications of Addison disease (29). Cardiovascular insufficiency, electrolyte and fluid imbalance, impaired carbohydrate metabolism, and poor nutritional status all contribute to the muscle weakness seen with adrenal insufficiency. The myopathy is rapidly corrected in most cases with glucocorticoid and mineralocorticoid replacement.

Biological basis

Etiology and pathogenesis

Generally, high dosages and long durations of therapy predispose patients to the development of corticosteroid myopathy. Patients receiving greater than 30 mg of prednisone a day are more likely to develop myopathy than those on lower doses or on alternate-day regimens (07). Patients receiving corticosteroids for less than 4 weeks rarely develop muscle weakness. However, individual sensitivity is an important factor, and the duration of therapy and steroid dose often correlate poorly with the degree of weakness.

All synthetic corticosteroid preparations used in clinical practice can produce myopathy. However, the risk of myopathy appears greater for the fluorinated corticosteroids: triamcinolone, betamethasone, and dexamethasone. In a review of 76 patients with corticosteroid myopathy, two thirds had been on triamcinolone or dexamethasone (02). Patients who develop myopathy on fluorinated agents may recover muscle strength when switched to equivalent doses of another corticosteroid.

Corticosteroids are proposed to cause myopathy through a variety of mechanisms. The main mechanism relates to impairment of protein and carbohydrate metabolism (29). Chronic low-dose corticosteroids induce protein catabolism primarily through diminished synthesis, but protein degradation dominates when higher doses are administered (61). Protein degradation has been associated with heightened skeletal muscle protease activity in some studies (43; 13). Protein catabolism is more prominent in type 2 fibers and is potentiated by sepsis and disuse. On the other hand, insulin induces an anabolic state on muscle, which may be antagonized by the insulin resistance produced by corticosteroids. The insulin-resistant state also alters carbohydrate metabolism, as shown by increased muscle glycogen deposition and marked reduction in glycolytic activity (18; 29). The significance of alterations in carbohydrate metabolism is unclear, as muscle ATP levels are not affected by corticosteroid treatment (56). Fibers with slow-twitch activity patterns and greater oxidative capacity, namely type 1, are considered more resistant to the effects of corticosteroids. Pathologically, type 2 muscle fiber atrophy is the hallmark of steroid myopathy.

Potassium and phosphate depletion caused by glucocorticoids is not an important factor in the generation of myopathy, because sarcolemmal excitability and excitation-contraction coupling are not significantly affected by corticosteroids (57). In addition, there is little evidence for motor nerve or neuromuscular junction dysfunction in corticosteroid myopathy, and these structures appear normal on electron microscopy even in the setting of severe muscle atrophy (12).

Massa and colleagues have shown that glucocorticoids cause focal loss of myosin in denervated rat muscle and that this process is reversed by reinnervation (42). Furthermore, immobilization has been shown to increase the concentration of glucocorticoid receptors in rat muscle (16). Pharmacological denervation of muscle by neuromuscular blocking agents may, therefore, enhance the myopathic potential of corticosteroids, resulting in the severe weakness seen in patients with acute steroid myopathy. Furthermore, several nondepolarizing neuromuscular blocking agents, including pancuronium and vecuronium, are aminosteroids and may act in a direct, additive manner to structurally related corticosteroids (20; 34). Rich and colleagues demonstrated that muscle may completely lose its excitability in some patients with acute steroid myopathy (53). An animal model using denervated muscle subsequently exposed to high-dose corticosteroids suggests that this loss of excitability results from inactivation of sodium channels (52).

Apoptotic cell death of differentiated skeletal muscle has been reported in a rat model of steroid-induced myopathy (37). In another rat model of critical illness myopathy, apoptosis-associated processes were differentially regulated in muscles of different function and fiber type (04). These authors concluded that interventions combating apoptosis may need to be directed towards inhibiting caspase-dependent as well as -independent mechanisms.

In a human muscle transcriptomics approach from 5 major muscular diseases, a dysregulation of genes in forward membrane pathway, responsible for transmitting action potential from neural excitation, was found to be unique to acute quadriplegic myopathy, thus, providing a biomarker and functional insight into dysregulation in this muscular disease (22).

The myopathy seen in pituitary and adrenal disease is believed to result from excess endogenous glucocorticoid production. In addition, elevated adrenocorticotropic hormone levels in Cushing disease may be independently myotoxic, as suggested by the focal necrosis produced by adrenocorticotropic hormone administration in rabbit muscle (19). The extensive lipid deposition also observed after adrenocorticotropic hormone administration is not typical of corticosteroid myopathy, again suggesting that adrenocorticotropic hormone may have unique myotoxic actions independent of glucocorticoid excess, although the exact pathophysiologic mechanism remains to be elucidated.

The myopathy seen in Addison disease likely results from a variety of metabolic derangements that accompany adrenal insufficiency, including changes in carbohydrate, water, and electrolyte balance as well as muscle blood flow (29). Myopathy is not an expected complication of adrenal insufficiency; severe weakness in a patient with Addison disease should prompt further investigation.

In critically ill patients, controlled mechanical ventilation (CMV) may lead to a rapid and profound loss of diaphragm function, referred to as ventilator-induced diaphragm dysfunction. In contrast to CMV, assisted mechanical ventilation (AMV) maintains partial neural activation and mechanical loading of the diaphragm and preserves its function. Sassoon and colleagues found in a rabbit model that high-dose methylprednisolone had no additive effects on CMV-induced diaphragm dysfunction but had a negative impact on the diaphragm-sparing properties of AMV creating a CMV-like effect (58). Subject to confirmation in patients, these observations may have high clinical relevance.

Glucocorticoid excess also has major effects on muscle protein synthesis and degradation and myoblast proliferation (47).

In cultured myotubes, ß-hydroxy-ß-methylbutyrate (HMB), a metabolite of the branched-chain amino acid leucine, attenuated dexamethasone-induced damage such as protein degradation, decreased protein synthesis, and reduced myotube size (03), probably via MAP kinase and PI3K/Akt signaling pathways. Because HMB supplementation in humans is safe and has already been effective in clinical studies of muscle wasting due to cancer, AIDS, and aging, its effect in corticosteroid myopathy may be investigated in a randomized clinical trial.

Epidemiology

Steroid myopathy is the most common form of endocrine muscle disease, a result of the widespread use of corticosteroids in clinical practice. Between 2.4% and 21% of patients receiving chronic corticosteroids develop significant myopathy. An even greater proportion of patients may develop some degree of muscle weakness. When quantitative strength testing is used, a majority of patients on chronic corticosteroid therapy will have reduced muscle peak torque and power (55). In contrast, glucocorticoid deficiency rarely causes myopathy (46). Corticosteroid myopathy has been reported in children and adults of all ages, with women and younger patients being more susceptible (09; 07). Cancer patients may be especially susceptible to corticosteroid myopathy, with 60% developing proximal weakness, typically during the first 2 weeks of therapy (06). Respiratory muscles are often affected in this population.

In a series of 27 consecutive patients treated with steroids and neuromuscular blocking agents for status asthmaticus, 4 (15%) developed severe quadriplegia (01). Creatine kinase levels were elevated in the 3 patients tested. However, the true incidence of this complication is still unknown. Hyperthyroidism may predispose to corticosteroid-induced myopathy (54).

An observational study of 36 patients with respiratory diseases (mostly asthma) showed that 65% of patients using corticosteroids daily over more than 1 year reported weakness in legs, and 20% of these patients demonstrated objective signs of muscle weakness. As the majority of patients in this study had been using inhaled steroids, the results do not support the view that inhaled steroids are safer than oral steroids (38).

Of course, with the recent emergence of COVID-19, several reports showed an associated muscle weakness due to critical illness myopathy. One of the obvious causes is high-dose corticosteroid given to COVID-19 patients to halt the autoimmune response. Care of corticosteroid administration is crucial to prevent such complications as monitoring CK levels, lowering the dose, and early mobilization (41).

Differential diagnosis

Diagnosing steroid myopathy is straightforward in patients receiving corticosteroids for disorders not characterized by muscle weakness. However, the diagnosis is more difficult in patients treated with glucocorticoids for disorders that themselves produce weakness. For instance, clinical deterioration in a patient receiving prednisone for inflammatory myopathy may result from corticosteroid myopathy or from a disease exacerbation. The inflammatory myopathy is more likely to be responsible if weakness occurs early in the course of corticosteroid therapy or if there are no other stigmata of glucocorticoid toxicity (29). Creatine kinase elevations also suggest that a flare of the inflammatory myopathy is the underlying cause. On the other hand, a predominance of lactic dehydrogenase 1, 2, and 3 isoenzymes in serum is indicative of corticosteroid myopathy (30) because this isoenzyme shift is not observed in inflammatory myopathy. EMG may be helpful in distinguishing drug toxicity from disease flares in that fibrillations are more common in inflammatory myopathy. Although type 2 atrophy in a muscle biopsy is nonspecific, persistence or progression of inflammation would suggest myositis.

Changes in creatine excretion may help distinguish the cause of deterioration (29) but only when a baseline is known. If the weakness is from corticosteroid toxicity, a dose reduction will lower creatine excretion. If the patient is experiencing a flare of the inflammatory process, a dose reduction will cause an increase in creatine excretion and further deterioration of muscle strength. The level of creatinuria has not been found to correlate with either the steroid dose or the degree of weakness (07).

Clinical, laboratory, and electrophysiologic data help distinguish acute steroid myopathy from other common causes of acute flaccid weakness in the intensive care setting, such as Guillain-Barré syndrome, myasthenia gravis, and critical illness polyneuropathy. Direct muscle stimulation may be particularly helpful in this clinical setting (53). Inexcitable muscle would predict that an acute quadriplegic myopathy is the cause of weakness.

Diagnostic workup

Serum creatine kinase levels are typically normal in chronic corticosteroid myopathy, whereas elevated urinary creatine excretion is commonplace (02). In most patients, creatine kinase is elevated early in the course of acute steroid myopathy, up to 400 times control levels (25). Early monitoring of creatine kinase levels in patients at risk may alert physicians to an evolving myopathy and the need to lower or discontinue corticosteroids and neuromuscular blocking agents (34).

EMG findings in corticosteroid myopathy are variable. Insertional activity is normal and, except for scattered reports of fibrillation potentials, abnormal spontaneous activity is usually absent (29). Fibrillations and complex repetitive discharges may occur in the myopathy of Cushing syndrome (33). Myopathic motor units are usually absent; however, they are rarely reported, especially in the setting of marked weakness or the acute form of steroid myopathy (31).

Critical illness myopathy may be associated with increased short duration units and spontaneous discharges in the affected proximal muscles (51).

Selective atrophy of fast-twitch glycolytic fibers (type 2b) is the classic histologic feature on muscle biopsy in myopathy from either exogenous corticosteroid toxicity or Cushing disease (29). Increased glycogen may be noted in type 2 fibers. Ultrastructural abnormalities include initial proliferation and aggregation of mitochondria followed by degeneration and mitochondrial loss. Muscle biopsies from some patients with acute steroid myopathy and quadriplegia show a selective loss of myosin filaments followed by degeneration of muscle fibers (62; 05). Type 2 myofiber atrophy with fiber necrosis and regeneration are the principal findings in other reports (23; 34). The distinctive loss of thick filaments may not be seen in biopsy specimens obtained in the first 2 weeks after corticosteroids are initiated (34).

When Cushing syndrome is suspected, a dexamethasone suppression test and urinary free cortisol are recommended to confirm the diagnosis (33). Diffuse fibrillations and myopathic motor units were seen in 80% to 90% of patients with the acute form of steroid myopathy (34). Patients were unable to activate motor unit potentials in severely affected muscles. On nerve conduction studies, motor amplitudes were typically reduced out of proportion to any reduction in sensory nerve action potentials, helping to distinguish these patients from those with critical illness polyneuropathy.

Utilization of ultrasonography of the muscle is helpful to monitor the progression of the disease and the early response to treatment. Change in muscles echogenicity can precede noticeable change in muscle strength examination. Echo intensity of the proximal lower limb muscle is increased in patients with Cushing syndrome, and a quantitative measurement can assess the changes induced by corticosteroid in muscle mass and structure (45).

Management

Stopping the corticosteroid, lowering the dose, and switching to a nonfluorinated preparation are the mainstays of management (29). Converting to an alternate-day dosing schedule may also improve muscle strength. Even with these measures, however, recovery may take months. Reducing endogenous glucocorticoid synthesis is the goal of treatment in patients with pituitary or adrenal hyperfunction. Muscle atrophy and weakness from Cushing disease resolve when corticosteroid levels normalize.

When glucocorticoids are tapered in the case of an underlying inflammatory muscle disease, the patient must be monitored for a flare of the underlying condition (in particular, rise of CK) and for signs of evolving adrenal insufficiency (11). Improved strength within 3 to 4 weeks after corticosteroid tapering is a good indicator that the weakness was indeed due to the drug and not to the underlying inflammatory muscle disease (50).

Although dietary supplementation in patients with adequate protein intake is not beneficial, exercise may partially protect muscle from glucocorticoid-induced atrophy. Immobilization has been shown to increase the concentration of glucocorticoid receptors in rat muscle (16), suggesting that inactivity may place patients at greater risk to develop corticosteroid myopathy. Furthermore, isokinetic physical training was found to reverse muscle atrophy and normalize strength in renal transplant patients receiving low to moderate doses of prednisone (27). Therefore, physical therapy may play an important role in the management of patients receiving chronic glucocorticoids.

A variety of medications including potassium supplements, phenytoin, vitamin E, and anabolic steroids have not proved effective in the prevention or management of corticosteroid myopathy (26). In rats, creatine supplementation attenuated corticosteroid-induced muscle wasting and impairment of exercise performance (44).

In general, corticosteroid myopathy is fully reversible when the steroid dosage is reduced below a threshold of prednisone 30 mg/day. Most promising for management of critical illness myopathy has been the demonstration of the feasibility and benefits of early, targeted physiotherapy, even while patients are undergoing life- and organ-support interventions (49). Mobilization of critically ill patients is safe and can be facilitated with modest additions of staff and equipment to the ICU. In a randomized controlled trial, investigators reported that early physical and occupational therapy, coupled with a sedative holiday, resulted in a reduction in the duration of mechanical ventilation, a reduction in days in the ICU, and near doubling of the fraction of patients who achieved independent functional status (59). Another randomized controlled trial showed that in addition to standard physiotherapy, patients who had initially passive and then active daily cycling exercises in the ICU had an improved 6-minute walking distance and physical satisfaction score at hospital discharge (10). If these benefits can be sustained and the results of these seminal trials confirmed in larger trials, early mobilization of patients may become a standard approach in critical illness myopathy (21).

Outcomes

Chronic corticosteroid myopathy is fully reversible when the medication is stopped or lowered below an equivalent of prednisone 30 mg a day (26). The prognosis is favorable in most patients with acute steroid myopathy. In a review, nearly 90% of patients improved, although only one half regained normal motor function (25). In both the acute and chronic forms, the recovery period may persist for months to years. Similarly, myopathy from increased endogenous production resolves when glucocorticoid levels normalize.

References

01: Apte-Kakade S. Rehabilitation of patients with quadriparesis after treatment of status asthmaticus with neuromuscular blocking agents and high-dose corticosteroids. Arch Phys Med Rehabil 1991;72:1024-8. PMID 1953316
02: Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976;61:485-92. PMID 973643
03: Aversa Z, Alamdari N, Castillero E, Muscaritoli M, Rossi Fanelli F, Hasselgren PO. β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy. Biochem Biophys Res Commun 2012;423(4):739-43. PMID 22705301
04: Barnes BT, Confides AL, Rich MM, Dupont-Versteegden EE. Distinct muscle apoptotic pathways are activated in muscles with different fiber types in a rat model of critical illness myopathy. J Muscle Res Cell Motil 2015; 36(3):243-53. PMID 25740800
05: Barohn RJ, Jackson CE, Rogers SJ, Ridings LW, McVey AL. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve 1994;17:647-54. PMID 7910951
06: Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997;48:1234-38. PMID 9153449
07: Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985;76:234-42. PMID 4019954
08: Braith RW, Welsch MA, Mills RM, Keller JW, Pollock ML. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc 1998;30:483-9. PMID 9565927
09: Bunch TW, Worthington JW, Combs JJ, Ilstrup MS, Engel AG. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980;92:365-9. PMID 6986827
10: Burtin C, Clerckx B, Robbeets C, et al. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med 2009;37(9):2499-505. PMID 19623052
11: Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. J Am Acad Dermatol 2017;76(2):201-7. PMID 28088991
12: Chokroverty S, Reyes MG, Chokroverty M, Kaplan R. Effect of prednisolone on motor end-plate fine structure: a morphometric study in hamsters. Ann Neurol 1978;3:358-65. PMID 666278
13: Clark AF, Vignos PJ. The role of proteases in experimental glucocorticoid myopathy. Muscle Nerve 1981;4:219-22. PMID 6264287
14: Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932;50:137-95.
15: Deconinck N, Van Parijs V, Beckers-Bleukx G, Van den Bergh P. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord 1998;8(3-4):186-92. PMID 9631400
16: DuBois DC, Almon RR. Disuse atrophy of skeletal muscle is associated with an increase in number of glucocorticoid receptors. Endocrinology 1980;107:1649-51. PMID 7428684
17: Dubois EL. Triamcinolone in the treatment of systemic lupus erythematosus. J Am Med Assoc 1958;167(13):1590-9. PMID 13563147
18: Fernandez-Sola J, Cusso R, Picado C, et al. Patients with chronic glucocorticoid treatment develop changes in muscle glycogen metabolism. J Neurol Sci 1993;117:103-6. PMID 8410044
19: Germuth FG, Nedzel GA, Ottinger B, Oyama J. Anatomic and histologic changes in rabbits with experimental hypersensitivity treated with compound E and ACTH. Proc Soc Exp Biol Med 1951;76:177-82. PMID 14816433
20: Gooch JL. AAEM case report #29: prolonged paralysis after neuromuscular blockade. Muscle Nerve 1995;18:937-42. PMID 7643872
21: Griffiths RD, Hall JB. Intensive care unit-acquired weakness. Crit Care Med 2010;38(3):779-87. PMID 20048676
22: Gupta S, Kim SM, Wang Y, Dinasarapu AR, Subramaniam S. Statistical insights into major human muscular diseases. Hum Mol Genet 2014;23(14):3772-8. PMID 24569163
23: Gutmann L, Blumenthal D, Gutmann L, Schochet SS. Acute type II myofiber atrophy in critical illness. Neurology 1996;46:819-21. PMID 8618690
24: Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 2009;(1):CD006832. PMID 19160304
25: Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992;42:2082-7. PMID 1436516
26: Hollister JR. The untoward effects of steroid treatment on the musculoskeletal system and what to do about them. J Asthma 1992;29:363-8. PMID 1429389
27: Horber FF, Scheidegger JR, Grunig BE, Frey FJ. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985;61:83-8. PMID 3998075
28: Hough CL, Steinberg KP, Taylor Thompson B, Rubenfeld GD, Hudson LD. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009;35(1):63-8. PMID 18946661
29: Kaminski HJ, Ruff RL. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pituitary, and parathyroid glands and iatrogenic corticosteroid myopathy). In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd ed. New York: McGraw-Hill, 1994:1726-53.
30: Kaneko K, Yamazaki O, Miyatake T. Correlation between steroid myopathy and the elevated serum lactic dehydrogenase (LDH) 1, 2, and 3 isoenzymes. Muscle Nerve 1993;16:1135-6. PMID 8413364
31: Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983;18(2):155-66. PMID 6851197
32: Kohler A, Jolliet P, Schnorf H, Magistris MR. Two identical episodes of acute quadriparesis in an intensive care unit patient. Intensive Care Med 1998;24:891-2. PMID 9757940
33: Lacomis D, Chad DA, Aronin N, Smith TW. The myopathy of Cushing's syndrome. Muscle Nerve 1993;16:880-1. PMID 8332144
34: Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996;40:645-54. PMID 8871585
35: Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 2011;10(10):931-41. PMID 21939902
36: Latronico N, Tomelleri G, Filosto M. Critical illness myopathy. Curr Opin Rheumatol 2012;24(6):616-22. PMID 22918529
37: Lee MC, Wee GR, Kim JH. Apoptosis of skeletal muscle on steroid-induced myopathy in rats. J Nutr 2005;135:1806-8S. PMID 15987869
38: Levin OS, Polunina AG, Demyanova MA, Isaev FV. Steroid myopathy in patients with chronic respiratory diseases. J Neurol Sci 2014;338(1-2):96-101. PMID 24380687
39: Lindenbaum Y, Nations SP, Barohn RJ, Wolfe GI. Recurrent critical illness myopathy in an asthmatic patient treated with corticosteroids. J Clin Neuromusc Dis 2000;1(3):145-6. PMID 19078575
40: MacFarlane I, Rosenthal F. Severe myopathy after status asthmaticus. Lancet 1977;2:615. PMID 71437
41: Madia F, Merico B, Primiano G, Cutuli SL, De Pascale G, Servidei S. Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Neurology 2020;95(11):492-4. PMID 32601119
42: Massa R, Carpenter S, Holland P, Karpati G. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve 1992;15:1290-8. PMID 1488068
43: Mayer M, Shafrir E, Kaiser N, Milholland RJ, Rosen F. Interaction of glucocorticoid hormones with rat skeletal muscle: catabolic effects and hormone binding. Metabolism 1976;25:157-67. PMID 175237
44: Menezes LG, Sobreira C, Neder L, Rodrigues-Junior AL, Martinez JA. Creatine supplementation attenuates corticosteroid-induced muscle wasting and impairment of exercise performance in rats. J Appl Physiol 2007;102:698-703. PMID 17053101
45: Minetto MA, Caresio C, DAngelo V, et al. Diagnostic evaluation in steroid-induced myopathy: case report suggesting clinical utility of quantitative muscle ultrasonography. Endocr Res 2018;43(4):4:235-45. PMID 29648902
46: Mor F, Green P, Wysenbeek AJ. Myopathy in Addison's disease. Ann Rheum Dis 1987;46:81-3. PMID 3813679
47: Morgan SA, Hassan-Smith ZK, Doig CL, Sherlock M, Stewart PM, Lavery GG. Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism. J Endocrinol 2016;229(3):277-86. PMID 27048233
48: Nava S, Fracchia C, Callegari G, Ambrosino N, Barbarito N, Felicetti G. Weakness of respiratory and skeletal muscles after a short course of steroids in patients with acute lung rejection. Eur Respir J 2002;20(2):497-9. PMID 12212986
49: Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA 2008;300(14):1685-90. PMID 18840842
50: Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78(1):41-4. PMID 20471889
51: Plaut T, Weiss L. Electrodiagnostic evaluation of critical illness myopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021. PMID 32965903
52: Rich MM, Pinter MJ. Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 2001;50:26-33. PMID 11456306
53: Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996;46:731-6. PMID 8618674
54: Riggs JE, Pandey HK, Schochet SS Jr. Critical illness myopathy associated with hyperthyroidism. Military Medicine 2004;169(1):71-2. PMID 14964506
55: Rothstein JM, Delitto A, Sinacore DR, Rose SJ. Muscle function in rheumatic disease patients treated with corticosteroids. Muscle Nerve 1983;6:128-35. PMID 6602291
56: Ruff RL. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pituitary, and parathyroid glands and iatrogenic steroid myopathy). In: Engel AG, Banker BQ, editors. Myology. New York: McGraw-Hill, 1986:1871-906.
57: Ruff RL, Martyn D, Gordon AL. Glucocorticoid-induced atrophy is not due to impaired excitability in rat muscle. Am J Physiol 1982;243:E512-21. PMID 7149022
58: Sassoon CS, Zhu E, Fang L, Ramar K, Jiao GY, Caiozzo VJ. Interactive effects of corticosteroid and mechanical ventilation on diaphragm muscle function. Muscle Nerve 2011;43(1):103-11. PMID 21171101
59: Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 2009;373(9678):1874-82. PMID 19446324
60: Sun DY, Edgar M, Rubin M. Hemiparetic acute myopathy of intensive care progressing to triplegia. Arch Neurol 1997;54:1420-2. PMID 9362992
61: Tomas FM, Murray AJ, Jones LM. Interactive effects of insulin and corticosterone on myofibrillar protein turnover in rats as determined by N tau-methylhistidine excretion. Biochem J 1984;220:469-79. PMID 6378188
62: Waclawik AJ, Sufit RL, Beinlich BR, Schutta HS. Acute myopathy with selective degeneration of myosin filaments following status asthmaticus. Neuromuscul Disord 1992;2:19-26. PMID 1356045
63: Weiner P, Azgad Y, Weiner M. Inspiratory muscle training during treatment with corticosteroids in humans. Chest 1995;107:1041-4. PMID 7705113

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Aziz I Shaibani MD

Dr. Shaibani of Baylor College of Medicine has no relevant financial relationships to disclose.
See Profile
Husam Al Sultani MD

Dr. Al Sultani of the Nerve and Muscle Center of Texas has no financial relationships to disclose.
See Profile

Editor

Aravindhan Veerapandiyan MD

Dr. Veerapandiyan of University of Arkansas for Medical Sciences has no relevant financial relationships to disclose.
See Profile

Former Authors

Richard Barohn MD (original author), David S Saperstein MD, Gil I Wolfe MD, and Thomas Klopstock MD

Patient Profile

Age range of presentation: 2 to 65+ years
Sex preponderance: female>male, >1:1
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Corticosteroid myopathy: 359.4

Endocrine myopathy: 259.9

Myopathy and endocrine disorders classified elsewhere: 359.5
ICD-10: Corticosteroid myopathy: G72.2

Endocrine myopathy: E34.9

Myopathy in endocrine diseases: G73.5

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Corticosteroid myopathies

Associated Disorders

Addison disease
Connective tissue disorders
Cushing disease
Cushing syndrome
Status asthmaticus

Differential Diagnosis

inflammatory myopathy
Guillain-Barre syndrome
myasthenia gravis
critical illness polyneuropathy

Also Relevant

Critical illness myopathy and polyneuropathy
Drug-induced myopathies
Chemotherapy: neurologic complications
Prednisone

Clinical Categories

Neuromuscular Disorders

Patient Handouts

Cushing's syndrome

Corticosteroid myopathies …

Corticosteroid myopathies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Special considerations

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Paraspinal neuromuscular syndromes

Dementia associated with amyotrophic lateral sclerosis

Collagen VI-related dystrophies: Ullrich congenital muscular dystrophy, Bethlem muscular dystrophy, and intermediate COL6-RD

Sleep and neuromuscular and spinal cord disorders

Periodic paralysis and the nondystrophic myotonias (skeletal muscle channelopathies)

Corticosteroid myopathies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Special considerations

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Paraspinal neuromuscular syndromes

Dementia associated with amyotrophic lateral sclerosis

Collagen VI-related dystrophies: Ullrich congenital muscular dystrophy, Bethlem muscular dystrophy, and intermediate COL6-RD

Sleep and neuromuscular and spinal cord disorders

Periodic paralysis and the nondystrophic myotonias (skeletal muscle channelopathies)

This is an article preview.
Start a Free Account
to access the full version.